Loading clinical trials...
Loading clinical trials...
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Anti-tumor Efficacy of HDM2024 in Participants With Advanced Solid Tumors
Conditions
Interventions
HDM2024
Locations
1
China
Shanghai East Hospital
Shanghai, Shanghai Municipality, China
Start Date
April 10, 2026
Primary Completion Date
April 15, 2027
Completion Date
December 28, 2028
Last Updated
April 20, 2026
NCT07360314
NCT07403721
NCT07524348
NCT03093116
NCT06898450
NCT05719558
Lead Sponsor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions